2,6-difluoro-N-(4-(5-methyl-2-(trifluoromethyl)oxazol-4-yl)phenyl)benzamide | 1582285-86-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,6-difluoro-N-(4-(5-methyl-2-(trifluoromethyl)oxazol-4-yl)phenyl)benzamide
• 英文别名: 2,6-difluoro-N-[4-[5-methyl-2-(trifluoromethyl)-1,3-oxazol-4-yl]phenyl]benzamide
• CAS: 1582285-86-6
• 化学式: C₁₈H₁₁F₅N₂O₂
• 分子量: 382.29
• InChiKey: VKDQNTHKASROTB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  N-[4-(2-氯丙酰基)苯基]乙酰胺 在 4-二甲氨基吡啶 、 水 、 溶剂黄146 、 N,N-二异丙基乙胺 、 三氟乙酸 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 37.33h， 生成 2,6-difluoro-N-(4-(5-methyl-2-(trifluoromethyl)oxazol-4-yl)phenyl)benzamide
  参考文献：
  名称：

  [EN] COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM
  [FR] COMPOSÉS MODULATEURS DE CALCIUM INTRACELLULAIRE

  摘要：

  本文描述了含有这些化合物的化合物和药物组合物，这些化合物调节储存操作钙（SOC）通道的活性。本文还描述了使用这种SOC通道调节剂的方法，单独或与其他化合物结合，用于治疗需要抑制SOC通道活性的疾病或病况。

  公开号：

  WO2014043715A1

文献信息

• Pyrazine-containing compound
  申请人：CalciMedica, Inc.

  公开号：US10821109B1

  公开（公告）日：2020-11-03

  Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling.

  本发明公开了与通过药物操纵钙信号改善胰腺炎有关的组合物和方法。此类组合物和方法可用于改善急性或慢性胰腺炎的症状，或降低高危人群患胰腺炎的几率或严重程度。在其他实施方案中，本文公开了与通过药物操纵钙信号转导改善病毒性疾病有关的组合物和方法。在进一步的实施方案中，本文公开了与通过药物操纵钙信号转导改善Th17诱导的疾病有关的组合物和方法。
• Pancreatitis treatment
  申请人：CALCIMEDICA, INC.

  公开号：US11311535B2

  公开（公告）日：2022-04-26

  Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling.

  本发明公开了与通过药物操纵钙信号改善胰腺炎有关的组合物和方法。此类组合物和方法可用于改善急性或慢性胰腺炎的症状，或降低高危人群患胰腺炎的几率或严重程度。在其他实施方案中，本文公开了与通过药物操纵钙信号转导改善病毒性疾病有关的组合物和方法。在进一步的实施方案中，本文公开了与通过药物操纵钙信号转导改善Th17诱导的疾病有关的组合物和方法。
• PANCREATITIS TREATMENT
  申请人：Calcimedica, Inc.

  公开号：EP3261641A1

  公开（公告）日：2018-01-03
• PYRAZINE-CONTAINING COMPOUND
  申请人：CalciMedica, Inc.

  公开号：US20200368228A1

  公开（公告）日：2020-11-26

  Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling.
• [EN] PANCREATITIS TREATMENT<br/>[FR] TRAITEMENT DE LA PANCRÉATITE
  申请人：CALCIMEDICA INC

  公开号：WO2016138472A1

  公开（公告）日：2016-09-01

  Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling.